Rosuvastatin - AstraZeneca
Alternative Names: Crestor; CRESTOR OD; Rosuvas; Rosuvastatin calcium; S 4522; ZD 4522Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Shionogi
- Developer AstraZeneca; Shionogi
- Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Discontinued Heart failure
Most Recent Events
- 02 Feb 2023 AstraZeneca and Oslo University withdraws before enrolment phase DECAMERONE II trial in Norway (PO) due to failure to include patients in Depressive disorder (NCT00951132)
- 12 Feb 2022 Pharmacodynamics data from phase II trial in Cardiovascular disorders presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
- 25 Jun 2021 Secondary analysis data from the phase III JUPITER trial in Cardiovascular disorders presented at 81st Annual Scientific Sessions of the American Diabetes Association(ADA-2021)